Literature DB >> 17403869

The type IV pilin of Burkholderia mallei is highly immunogenic but fails to protect against lethal aerosol challenge in a murine model.

Paula J Fernandes1, Qin Guo, David M Waag, Michael S Donnenberg.   

Abstract

Burkholderia mallei is the cause of glanders and a proven biological weapon. We identified and purified the type IV pilin protein of this organism to study its potential as a subunit vaccine. We found that purified pilin was highly immunogenic. Furthermore, mice infected via sublethal aerosol challenge developed significant increases in titers of antibody against the pilin, suggesting that it is expressed in vivo. Nevertheless, we found no evidence that high-titer antipilin antisera provided passive protection against a sublethal or lethal aerosol challenge and no evidence of protection afforded by active immunization with purified pilin. These results contrast with the utility of type IV pilin subunit vaccines against other infectious diseases and highlight the need for further efforts to identify protective responses against this pathogen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403869      PMCID: PMC1932848          DOI: 10.1128/IAI.00150-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

Review 1.  Biological weapons--a primer for microbiologists.

Authors:  R J Hawley; E M Eitzen
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

2.  In vitro antibiotic susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth microdilution and E-test.

Authors:  H S Heine; M J England; D M Waag; W R Byrne
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

Review 3.  Type IV pilus structure and bacterial pathogenicity.

Authors:  Lisa Craig; Michael E Pique; John A Tainer
Journal:  Nat Rev Microbiol       Date:  2004-05       Impact factor: 60.633

4.  A type IV pilin, PilA, Contributes To Adherence of Burkholderia pseudomallei and virulence in vivo.

Authors:  Angela E Essex-Lopresti; Justin A Boddey; Richard Thomas; Martin P Smith; M Gill Hartley; Timothy Atkins; Nat F Brown; Chuk Hai Tsang; Ian R A Peak; Jim Hill; Ifor R Beacham; Richard W Titball
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

5.  First shots fired in biological warfare.

Authors:  M Wheelis
Journal:  Nature       Date:  1998-09-17       Impact factor: 49.962

6.  DsbA is required for stability of the type IV pilin of enteropathogenic escherichia coli.

Authors:  H Z Zhang; M S Donnenberg
Journal:  Mol Microbiol       Date:  1996-08       Impact factor: 3.501

7.  Nonviable Burkholderia mallei induces a mixed Th1- and Th2-like cytokine response in BALB/c mice.

Authors:  Kei Amemiya; Gary V Bush; David DeShazer; David M Waag
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

8.  The use of synthetic peptides in the design of a consensus sequence vaccine for Pseudomonas aeruginosa.

Authors:  P J Cachia; L M Glasier; R R Hodgins; W Y Wong; R T Irvin; R S Hodges
Journal:  J Pept Res       Date:  1998-10

9.  The protective efficacy of cloned Moraxella bovis pili in monovalent and multivalent vaccine formulations against experimentally induced infectious bovine keratoconjunctivitis (IBK).

Authors:  A W Lepper; J L Atwell; P R Lehrbach; C L Schwartzkoff; J R Egerton; J M Tennent
Journal:  Vet Microbiol       Date:  1995-07       Impact factor: 3.293

10.  Impact of inhalation exposure modality and particle size on the respiratory deposition of ricin in BALB/c mice.

Authors:  Chad J Roy; Martha Hale; Justin M Hartings; Louise Pitt; Steven Duniho
Journal:  Inhal Toxicol       Date:  2003-05       Impact factor: 2.724

View more
  11 in total

1.  Flagellar glycosylation in Burkholderia pseudomallei and Burkholderia thailandensis.

Authors:  Andrew E Scott; Susan M Twine; Kelly M Fulton; Richard W Titball; Angela E Essex-Lopresti; Timothy P Atkins; Joann L Prior
Journal:  J Bacteriol       Date:  2011-05-20       Impact factor: 3.490

2.  Identification, immunogenicity, and cross-reactivity of type IV pilin and pilin-like proteins from Clostridium difficile.

Authors:  Grace A Maldarelli; Leon De Masi; Erik C von Rosenvinge; Mihaela Carter; Michael S Donnenberg
Journal:  Pathog Dis       Date:  2014-02-18       Impact factor: 3.166

Review 3.  Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Sara K Bondi; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

4.  Distinct human antibody response to the biological warfare agent Burkholderia mallei.

Authors:  John J Varga; Adam Vigil; David DeShazer; David M Waag; Philip Felgner; Joanna B Goldberg
Journal:  Virulence       Date:  2012-10-01       Impact factor: 5.882

5.  Epitope mapping immunodominant regions of the PilA protein of nontypeable Haemophilus influenzae (NTHI) to facilitate the design of two novel chimeric vaccine candidates.

Authors:  Laura A Novotny; Leanne D Adams; D Richard Kang; Gregory J Wiet; Xueya Cai; Sanjay Sethi; Timothy F Murphy; Lauren O Bakaletz
Journal:  Vaccine       Date:  2009-08-22       Impact factor: 3.641

6.  The Autotransporter BpaB Contributes to the Virulence of Burkholderia mallei in an Aerosol Model of Infection.

Authors:  Shawn M Zimmerman; Frank Michel; Robert J Hogan; Eric R Lafontaine
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

7.  Novel Burkholderia mallei virulence factors linked to specific host-pathogen protein interactions.

Authors:  Vesna Memisević; Nela Zavaljevski; Rembert Pieper; Seesandra V Rajagopala; Keehwan Kwon; Katherine Townsend; Chenggang Yu; Xueping Yu; David DeShazer; Jaques Reifman; Anders Wallqvist
Journal:  Mol Cell Proteomics       Date:  2013-06-24       Impact factor: 5.911

8.  A Burkholderia pseudomallei Outer Membrane Vesicle Vaccine Provides Cross Protection against Inhalational Glanders in Mice and Non-Human Primates.

Authors:  Sarah M Baker; Christopher J H Davitt; Natalya Motyka; Nicole L Kikendall; Kasi Russell-Lodrigue; Chad J Roy; Lisa A Morici
Journal:  Vaccines (Basel)       Date:  2017-12-09

9.  Outer Membrane Vesicle Vaccines from Biosafe Surrogates Prevent Acute Lethal Glanders in Mice.

Authors:  Michael H Norris; Mohammad S R Khan; Sunisa Chirakul; Herbert P Schweizer; Apichai Tuanyok
Journal:  Vaccines (Basel)       Date:  2018-01-10

10.  Phenotypic Characterization of a Novel Virulence-Factor Deletion Strain of Burkholderia mallei That Provides Partial Protection against Inhalational Glanders in Mice.

Authors:  Joel A Bozue; Sidhartha Chaudhury; Kei Amemiya; Jennifer Chua; Christopher K Cote; Ronald G Toothman; Jennifer L Dankmeyer; Christopher P Klimko; Catherine L Wilhelmsen; Jolynn W Raymond; Nela Zavaljevski; Jaques Reifman; Anders Wallqvist
Journal:  Front Cell Infect Microbiol       Date:  2016-02-26       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.